# Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment

> **NCT00332306** · PHASE3 · UNKNOWN · sponsor: **Tuberculosis Research Centre, India** · enrollment: 180 (estimated)

## Conditions studied

- Tuberculosis
- Human Immunodeficiency Virus Infections

## Interventions

- **DRUG:** Didanosine, Lamivudine, Efavirenz
- **DRUG:** Didanosine, Lamivudine, Nevirapine

## Key facts

- **NCT ID:** NCT00332306
- **Lead sponsor:** Tuberculosis Research Centre, India
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-06
- **Primary completion:** 2009-06
- **Final completion:** 2011-12
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2009-10-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00332306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00332306, "Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00332306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*